Showing 5041-5050 of 8207 results for "".
- Dermira Presents Positive Data on Treating Pediatric Patients with Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermira-presents-positive-data-on-treating-pediatric-patients-with-axillary-hyperhidrosis/2457873/Dermira, Inc. presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program showing that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediat
- Ortho Dermatologics Presents Analysis of Siliq Phase 3 Data on Disease-Related Anxiety and Depression in Patients with Psoriasishttps://practicaldermatology.com/news/ortho-dermatologics-presents-analysis-of-siliq-phase-3-data-on-disease-related-anxiety-and-depression-in-patients-with-psoriasis/2457875/Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC, shared the results from an analysis of the Phase 3 clinical trial AMAGINE-1, which evaluated mental health comorbidities associated with psoriasis, such as anxiety and depression. These findings were presented for the
- Exciplex Phototherapy Device Debuts at AAD 2018https://practicaldermatology.com/news/exciplex-phototherapy-device-debuts-at-aad-2018/2457877/Excimer Therapies Inc., now has the exclusive U.S. distribution rights for the Clarteis SAS exciplex® phototherapy treatment device. Excimer Therapies officially enters the market and will demonstrate the exciplex during t
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Aqua Pharmaceuticals Supports Camp Discoveryhttps://practicaldermatology.com/news/aqua-pharmaceuticals-supports-camp-discovery/2457884/Aqua Pharmaceuticals, LLC is demonstrating its commitment to the dermatology community by supporting American Academy of Dermatology’s Camp Discovery and is making a donation up to $5,000 to support the camp
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meetinghttps://practicaldermatology.com/news/zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting/2457886/Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Na
- FDA Accepts Ortho Dermatologics' NDA For Jemdel Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-jemdel-plaque-psoriasis-treatment/2457889/The FDA has accepted the New Drug Application for Jemdel (halobetasol propionate 0.01%) (IDP-122) lotion from Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. If approved, Jemdel will be the first high-potency topical steroid treatment for plaque psoriasis with dosin
- Denova Research and Illinois Dermatology Institute Partner for Clinical Researchhttps://practicaldermatology.com/news/denova-research-and-illinois-dermatology-institute-partner-for-clinical-research/2457894/DeNova Research is partnering with Illinois Dermatology Institute to become one of the largest and most comprehensive Dermatologic and Cosmetic Clinical Research sites in the Midwest. Denova Research has over 10 years’ experience, 110 publications and 76 clinical trials; many of whi
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications